Indication
Invasive
5 clinical trials
9 products
1 drug
Clinical trial
A Phase 3, Randomized, Blinded, Active-controlled Study to Evaluate the Immunogenicity and Safety of Walvax's 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13-TT) as Compared to Pfizer's 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Co-administered With EPI Vaccines at 2, 4, and 12-15 Months of Age, to Healthy Infants in IndonesiaStatus: , Estimated PCD: 2024-12-01
Product
Walvax PCV13-TTProduct
Pfizer PCV13Product
PCV13Clinical trial
Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral Ibrexafungerp (SCY-078) as an Emergency Use Treatment for Patients With Candidiasis, Including Candidemia, Caused by Candida AurisStatus: Completed, Estimated PCD: 2023-04-14
Product
SCY-078Clinical trial
A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin Followed by Oral Ibrexafungerp Versus Intravenous Echinocandin Followed by Oral Fluconazole (MARIO)Status: , Estimated PCD: 2024-06-01
Product
EchinocandinProduct
FluconazoleClinical trial
An Interventional Efficacy and Safety Phase 3 Double-blind 2-arm Study to Investigate IV Followed by Oral Fosmanogepix Compared With IV Caspofungin Followed by Oral Fluconazole in Adult Participants With Candidemia and/or Invasive CandidiasisStatus: Not yet recruiting, Estimated PCD: 2027-07-15
Product
FosmanogepixProduct
CaspofunginDrug
VarlilumabClinical trial
Open-Label, Randomized Study to Estimate Safety, PK, and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Standard-of-Care Following IV Echinocandin Therapy in the Treatment of Invasive Candidiasis in Hospitalized Nonneutropenic AdultsStatus: Completed, Estimated PCD: 2016-06-01
Product
Micafungin